2022 AUA Guidelines Update

We are excited to announce that the AUA have updated their guidelines to include recommending the use of genomic assays, such as the Oncotype DX® GPS test, for localized prostate cancer patients when added risk-stratification may alter clinical decision making.

ASCO Guidelines

Updated ASCO Guidelines strongly recommend use of the Oncotype DX Breast Recurrence Score® Test in node-negative and the majority of node-positive early-stage breast cancer patients

Live Webinar Event on June 15th

A Panel Discussion

Join Drs. Swapnil Rajurkar, Snehal Thakkar, and Joshua Routh as they discuss the value and implications of comprehensive genomic profiling (CGP) using real-life case studies.

AUA 2022

May 12-16th, 2022 in New Orleans, LA

Visit us at booth 647 for exclusive access to the 2022 Guidelines at a Glance Prostate Cancer Edition.
Making cancer care smarter.®